Related Experiment Videos
Total androgen blockade for metastatic cancer of the prostate
G Béland1, M Elhilali, Y Fradet
1Service of Urology, Notre-Dame Hospital, University of Montreal, Québec, Canada.
American Journal of Clinical Oncology
|January 1, 1988
Abstract:
This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.